These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33692941)

  • 1. Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma.
    Suzuki T; Kano S; Suzuki M; Yasukawa S; Mizumachi T; Tsushima N; Hatanaka KC; Hatanaka Y; Matsuno Y; Homma A
    Front Oncol; 2020; 10():603717. PubMed ID: 33692941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of mammaglobin in salivary duct carcinomas de novo and salivary duct carcinoma ex pleomorphic adenoma.
    Soares CD; de Lima Morais TM; Carlos R; Martins MD; de Almeida OP; Mariano FV; Altemani A
    Hum Pathol; 2019 Oct; 92():59-66. PubMed ID: 31400353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.
    Bahrami A; Perez-Ordonez B; Dalton JD; Weinreb I
    Histopathology; 2013 Aug; 63(2):250-62. PubMed ID: 23738717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
    Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.
    Takase S; Kano S; Tada Y; Kawakita D; Shimura T; Hirai H; Tsukahara K; Shimizu A; Imanishi Y; Ozawa H; Okami K; Sato Y; Sato Y; Fushimi C; Okada T; Sato H; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Hanazawa T; Chazono H; Osamura RY; Nagao T
    Oncotarget; 2017 Aug; 8(35):59023-59035. PubMed ID: 28938615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts.
    Katabi N; Ghossein R; Ho A; Dogan S; Zhang L; Sung YS; Antonescu CR
    Hum Pathol; 2015 Jan; 46(1):26-33. PubMed ID: 25439740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGA2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma ex-pleomorphic adenoma.
    Mito JK; Jo VY; Chiosea SI; Dal Cin P; Krane JF
    Histopathology; 2017 Oct; 71(4):511-521. PubMed ID: 28463429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities.
    Katabi N; Xu B; Jungbluth AA; Zhang L; Shao SY; Lane J; Ghossein R; Antonescu CR
    Histopathology; 2018 Jan; 72(2):285-293. PubMed ID: 28796899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
    Chiosea SI; Thompson LD; Weinreb I; Bauman JE; Mahaffey AM; Miller C; Ferris RL; Gooding WE
    Cancer; 2016 Oct; 122(20):3136-3144. PubMed ID: 27379604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
    Andreasen S; von Holstein SL; Homøe P; Heegaard S
    Acta Ophthalmol; 2018 Nov; 96(7):e768-e771. PubMed ID: 29437290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
    Shimura T; Tada Y; Hirai H; Kawakita D; Kano S; Tsukahara K; Shimizu A; Takase S; Imanishi Y; Ozawa H; Okami K; Sato Y; Sato Y; Fushimi C; Takahashi H; Okada T; Sato H; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Ando M; Kohsaka S; Hanazawa T; Chazono H; Kadokura Y; Kobayashi H; Nagao T
    Oncotarget; 2018 Jan; 9(2):1852-1867. PubMed ID: 29416736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acantholytic Squamous Cell Carcinoma and Salivary Duct Carcinoma Ex-pleomorphic Adenoma of the Submandibular Gland: A Report of Two Extremely Rare Cases with an Immunohistochemical Analysis.
    Kusafuka K; Kawasaki T; Onitsuka T; Hamaguchi N; Morita K; Mukaigawa T; Nishiya Y; Kamijo T; Iida Y; Nakajima T; Sugino T
    Head Neck Pathol; 2020 Mar; 14(1):230-238. PubMed ID: 30484070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
    Saigusa N; Hirai H; Tada Y; Kawakita D; Nakaguro M; Tsukahara K; Kano S; Ozawa H; Kondo T; Okami K; Togashi T; Sato Y; Urano M; Kajiwara M; Shimura T; Fushimi C; Shimizu A; Okamoto I; Okada T; Suzuki T; Imanishi Y; Watanabe Y; Sakai A; Ebisumoto K; Sato Y; Honma Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Takahashi H; Ando M; Kohsaka S; Matsuki T; Nagao T
    Front Oncol; 2021; 11():779882. PubMed ID: 35186711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study.
    Matsubayashi S; Yoshihara T
    Eur Arch Otorhinolaryngol; 2007 Jul; 264(7):789-95. PubMed ID: 17310348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma.
    Griffith CC; Thompson LD; Assaad A; Purgina BM; Lai C; Bauman JE; Weinreb I; Seethala RR; Chiosea SI
    Histopathology; 2014 Dec; 65(6):854-60. PubMed ID: 24804831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma: genomic profiles, gene fusions, and clinical characteristics.
    von Holstein SL; Fehr A; Persson M; Nickelsen M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
    Ophthalmology; 2014 May; 121(5):1125-33. PubMed ID: 24468654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
    Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
    Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers.
    Khurram SA; Speight PM
    Head Neck Pathol; 2019 Jun; 13(2):140-148. PubMed ID: 29671211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.